Free shipping on all orders over $ 500

Wortmannin

Cat. No. M2053
Wortmannin Structure
Synonym:

SL-2052

Size Price Availability Quantity
5mg USD 64.8  USD72 In stock
10mg USD 104.4  USD116 In stock
25mg USD 198  USD220 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Wortmannin (SL-2052) is a potent and specific PI3K inhibitor. The 50% inhibitory concentration for inhibition by wortmannin is 2 to 4 nM. Wortmannin inhibits polo-like kinase 1 (PLK1) with IC50 of 5.8 nM. Wortmannin displays a similar potency in vitro for the class I, II, and III PI3K members although it can also inhibit other PI3K-related enzymes such as mTOR, DNA-PK, some phosphatidylinositol 4-kinases, myosin light chain kinase (MLCK) and mitogen-activated protein kinase (MAPK) at high concentrations.

Product Citations
Customer Product Validations & Biological Datas
Source J Infect Dis (2018). Figure 7. Wortmannin (Abmole Bioscience)
Method Western blotting
Cell Lines mast cells
Concentrations 10 μM
Incubation Time 30 minutes
Results The S. aureus-induced production of TNF-α and CRAMP was significantly reduced by pretreatment with the specific PI3K inhibitor Wortmannin or the specific NF-κB inhibitor PDTC
Source APMIS.m (2017). Figure 7. wortmannin (Abmole Bioscience Inc. Houston, TX, USA)
Method Western blot
Cell Lines HeLa cells
Concentrations
Incubation Time
Results Moreover, cell pretreatment with wortmannin could reduce the expression level of p-PI3K, followed by slight augmentation in the inhibitory effects of 10-G on HeLa cells.
Protocol
Cell Experiment
Cell lines Human pancreatic adenocarcinoma cell lines PK1 and PK8
Preparation method Drug Treatments. For flow cytometric analysis, cells were treated with the drug vehicle (≤1% DMSO) or 20 μM gemcitabine (2′,2′-diflurodeoxycytidine; Eli Lily & Co., Indianapolis, IN) for 48 h or with the same concentration of gemcitabine for the same duration followed by wortmannin (50–400 nM) or LY294002 (15–120 μM) for 4 h in the continuous presence of gemcitabine. The concentration and duration of gemcitabine treatment were chosen based on preliminary studies examining its effects on cell cycle inhibition and induction of apoptosis. For Western blotting, cells were treated with similar concentrations of wortmannin or LY294002 alone for 4 h or with gemcitabine (20 and 40μ M) alone for 48 h before harvest. Wortmannin and LY294002 were purchased from Biomol (Philadelphia, PA). All compounds were dissolved in DMSO at a stock concentration of 10 mM, stored at −20°C, and added to cell cultures at a final concentration of ≤1% DMSO, with appropriate solvent additions to control cultures. All experiments were performed in triplicate.
Concentrations 50–400 nM
Incubation time 48 h
Animal Experiment
Animal models mice bearing Orthotopic Model
Formulation dissolved at 0.4 mg/ml in DMSO, and diluted with 0.9% NaCl before use.
Dosages single bolus injections of 0.7 mg/kg
Administration via the tail vein
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 428.43
Formula C23H24O8
CAS Number 19545-26-7
Purity 99.87%
Solubility DMSO 78 mg/mL
Storage at -20°C
References

Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.
Wymann MP, et al. Mol Cell Biol. 1996 Apr;16(4):1722-33. PMID: 8657148.

Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Powis G, et al. Cancer Res. 1994 May 1;54(9):2419-23. PMID: 8162590.

Related PI3K Products
Linperlisib (YY-20394)

Linperlisib, also known as YY-20394 and PI3Kδ-IN-2, is a potent and selective PI3Kδ inhibitor.

Leniolisib

Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor with IC50 of 11 nM.

Seletalisib

Seletalisib (UCB5857) is a potent and selective PI3Kδ inhibitor, with IC50 of 12 nM.

Glaucocalyxin A

Glaucocalyxin A is an ent-kauranoid diterpene from Rabdosia japonica var.

BAY1082439

BAY1082439 is an orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Wortmannin, SL-2052 supplier, PI3K, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.